Drugs based on small molecules represent the largest percentage of marketed pharmaceutical products and candidate compounds in drug-development pipelines worldwide. Secure sourcing of these active pharmaceutical ingredients (APIs) – as well as the intermediates from which they are developed – is critical in successful drug development and manufacturing programs. Adherence to stringent quality standards for early and advanced intermediates is also vital in ensuring an uninterrupted supply of drugs that patients depend upon.

We offer tailored services that can help you minimize cost and improve supply-chain security and stability in the production of early intermediates. Our integrated capabilities in Visp, Switzerland have flexible capacity in place for your production needs. The high-quality outcome of our work builds upon 40 years of experience across chemistry platforms.

Our Offering

Reliable global supply

  • Extensive manufacturing and global distribution chain
  • Certified quality systems and precise tracking systems
  • Integrated and scalable supply-chain solutions

Reduced complexity

  • Integrated supply of early intermediates, advanced intermediates, and API
  • Seamless scalability from development through commercialization
  • Certified quality systems (ISO and cGMP)

Enhanced value

  • Extensive chemical synthesis development and manufacturing track record
  • Track record of meeting accelerated development timelines
  • Dedicated staff and expertise in supply chain management, quality systems, and regulatory services

Contact us 

For more information, please email early.intermediates@lonza.com.

Webinar on-demand: The journey to a successful Biologics License Application (BLA)
Learn More
Recent webinar in the small molecule field:
Using health-based exposure limits (HBELs) to assess risk
Register Now